|
According to Thompson CenterWatch, 20 to 30 percent of clinical trials are being conducted in the ascending regions – India, China and Russia – due in large part to benefits such as:
- access to large, drug-naïve populations
- lower trial operating costs
- the ability to rapidly recruit suitable participants
This focus on end-benefits, however, fails to consider the deep challenges of the launch process itself, and companies who are not yet globally-proficient are likely to underestimate the critical role translation plays in that effort.
This Lionbridge white paper offers an experience-based overview of the global clinical trials translation process, including:
- issues and challenges of global trial communication
- planning for translation
- best practices for clinical trials translation
|
|
 |